November 19, 2012

GLOBAL ENGINEERING & STRATEGY

U.S. Equity Derivatives Flow Commentary New Market Develops in VIX Futures as TAS Volumes Increase

This document is not a product of Société Générale's research department and should not be regarded as a research report. It is a desk note by the SG Americas Securities, LLC, Flow Equity Derivatives Desk. It is only directed to Institutional Investors (as defined under NASD Rule 2211 of the Financial Industry Regulatory Authority, Inc.) and available only to such Institutional Investors who have received the proper options risk disclosure documents. In addition, for the sole purpose of CFTC Rule 1.71(a)(9), to the extent the market or trading commentary contained herein includes an analysis of a price of a derivative and contains information reasonably sufficient to base a decision to enter into a derivatives transaction, it is conveyed as a solicitation for entering into a derivatives transaction

Overview:

We show how the VIX trade-at-settlement (TAS) has been affected by the increased popularity of VIX indexation, including Equity Traded Notes (ETN) and Equity Traded Funds (ETFs) tracking VIX indices.

What is TAS for the VIX Futures?

- Market participants are be able to enter VIX futures orders in a TAS order book during the trading day at a price equal to that day's VIX futures settlement price, or at a specified differential above or below the daily settlement price. e.g., price increments can be higher or lower than the daily settlement price. Completed TAS transactions are confirmed during the trading session, and the final price of the transaction is confirmed when the daily settlement price is established (see link CBOE VIX TAS).
- TAS transactions help traders during the day to manage their exposure in VIX futures related to traded notes (ETNs) and exchange traded funds (ETFs) by receiving more price certainty relative to the daily settlement price.
- For the purposed of this piece, we define that the "TAS differential" is the specified difference above or below the settlement price. This means that settlement plus the TAS differential results in the trade-at-settlement VIX futures price. For an example of how we use TAS, see Appendix I.

Why has TAS volume been increasing for the VIX Futures?

We have seen an increase in TAS volume related to the increased popularity and trading activity of VIX indexation (ETNs and ETFs). Increased volumes in the TAS mechanism generally occur as trades below settlement. Since mid-April, we have seen that the volume weighted TAS differential is generally negative for the onthe-run 2 to 7 month VIX futures. Due to the lack of liquidity for the 8 and 9 month VIX futures, we do not see any TAS volume.

Conclusions:

- Although TAS volumes for on-the-run UX1 and UX2 VIX futures contracts have been increasing, figure 1 shows the even TAS volumes on less liquid 3 to 7 month on-the-run VIX futures have been increasing since mid-April.
- Our experience is that a negative TAS differential is the result of VIX indexers managing their risk against indexes calculated using settlement prices. The settlement price is determined by rounding up from the midpoint of the bid-ask to the nearest tick (\$0.05 increment) and thereby, it is generally disadvantageous to sellers relative to buyers of the VIX futures. VIX future buyers can buy at or near settlement (offer) but sellers of the VIX future will have generally trade below settlement (bid) with a negative TAS spread.

Fig. 1 Increase VIX Futures TAS Volume for 3-Mth through 7-Mth maturities (4/16/12 to 11/9/12)




Table 1 shows the mean and median of the daily volume weighted TAS differential over time on an actual and absolute value basis as well as last 22-day average of volume weighted TAS differential on an actual and absolute basis. We can see that the effect is most prominent on the 2 to 7 month VIX futures (UX2 through UX7).

Table 1. Statistics for Volume Weighted TAS Differential from 4/16/12 to 11/9/12

VIX Future	VIX On-The- Run Maturity (Months)	Volume Weighted TAS Differential as of 11/9/12	Mean of Daily Volume Weighted TAS Differential (4/16/12 to 11/9/12)	Median of Daily Volume Weighted TAS Differential (4/16/12 to 11/9/12)	22-Day Avg. of Volume Weighted TAS Differential (10/9/12 to 11/9/12)	TAS Differential	22-Day Avg. of Absolute Value of Volume Weighted TAS Differential (10/9/12 to 11/9/12)
UX1	1	-0.006	-0.002	-0.002	0.000	0.002	0.002
UX2	2	-0.026	-0.024	-0.027	-0.030	0.027	0.030
UX3	3	-0.015	-0.020	-0.020	-0.019	0.020	0.019
UX4	4	-0.022	-0.016	-0.019	-0.022	0.019	0.022
UX5	5	-0.020	-0.015	-0.013	-0.021	0.014	0.021
UX6	6	-0.021	-0.014	-0.014	-0.019	0.014	0.019
UX7	7	-0.027	-0.018	-0.018	-0.026	0.018	0.026

Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

BUILDING TEAM SPIRIT TOGETHER



One-Delta Trading Engineering & Strategy

Ramon Verastegui James Hosker

Shuwen Zhao

frank.nies@sgcib.com

+1 212 278 5969


ramon.verastegui@sgcib.com

james.hosker@sgcib.com shuwen.zhao@sgcib.com +1 212 278 7548 +1 212 278 6291

Since mid-April, **Table 1** also shows that for most of the on-the-run VIX futures, the median and mean of the daily volume weighted TAS differentials are close to one another. However, there are differences between the actual median and mean of the daily volume weighted TAS differentials for UX1 and UX2. This implies that there can be negative and positive TAS values from the settlement. Alternatively, there is little difference between actual and absolute medians for the 3 month to 7 month VIX futures. For the front UX1 (1-mth) VIX futures contract, we have a mean and median as well as 22-day averages close to zero due to the very liquid trading of this front month future.

Since April 2012, **figure 2** shows that TAS volume as a percent of the total VIX futures volume has been increasing across most VIX futures maturities (UX1 through UX7).

Fig. 2 TAS Volume (To-Date) is Increasing Across most all VIX Futures Maturities as Percent of Total Daily VIX Futures Volume (4/16/12 to 11/9/12)





Figures 3, 4, 5, 6, 7, 8 and 9 show that the daily volume weighted TAS differentials for the on-the-run 1, 2, 3, 4, 5, 6 and 7 month VIX futures, respectively, has been widening and becoming more negative over the last few months. In addition, the 22- day

average spread on the daily volume weighted TAS has widened becoming more negative. In addition, the figures show that TAS volume and the 22-day average TAS volume have been generally increasing for all VIX futures maturities over the last few months. However, the TAS volume and 22-day average TAS volume for the 3 and 6-month VIX on-the-run (UX3) has decrease over the last month. Using over 30 listed ETN products on VIX futures as a proxy for the OTC market, we find that most are using to the front month contracts UX1 and UX2 and others are using UX4, UX5 and UX7. However, there are very few using the UX3 and UX6 contracts, which can contribute to lower volumes.

With the exception of the front-month VIX futures (UX1) where the volume weighted TAS differential is generally close to zero, for most other maturities, the TAS differential has been negative. Therefore, VIX futures settlement generally becomes the offer due to the midmarket rounding up to the nearest tick while the bid is generally below the settlement price with a negative TAS differential, except for the 1-mth VIX futures contract.

Fig. 3 1-mth VIX (UX1) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)





Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

One-Delta Trading Engineering & Strategy

Ramon Verastegui James Hosker Shuwen Zhao frank.nies@sgcib.com

+1 212 278 5969

ramon.verastegui@sgcib.com james.hosker@sgcib.com shuwen.zhao@sgcib.com +1 212 278 7548 +1 212 278 6291 +1 212 278 7268

Fig. 4 2-mth VIX (UX2) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)

Fig. 5 3-mth VIX (UX3) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)






Fig. 6 4-mth VIX (UX4) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)




UX4 TAS Volume (LHS) 22-Day Avg TAS Volume UX4 (RHS) 900 500 Volume Number of Contracts 450 800 400 700 350 600 300 500 250 400 200 300 150 200 100 100 50 7/9/12 123/12 8/6/12 8/20/12 9/3/12 9/17/12 10/1/12 0/15/12 0/29/12 4/16/12 5/14/12 5/28/12 6/11/12 6/25/12

Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

Fig. 7 5-mth VIX (UX5) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)






Source: Bloomberg, SG Global Engineering & Strategy, SG Trading


Ramon Verastegui James Hosker Shuwen Zhao frank.nies@sgcib.com

+1 212 278 5969

ramon.verastegui@sgcib.com james.hosker@sgcib.com shuwen.zhao@sgcib.com +1 212 278 7548 +1 212 278 6291


Fig. 8 6-mth VIX (UX6) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)






Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

Fig. 9 7-mth VIX (UX7) Volume Weight TAS Differential, Last 22-Day Avg. TAS Differential, Daily TAS Volume, & 22-Day Avg. TAS Volume (4/16/12 to 11/9/12)





Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

Ramon Verastegui James Hosker Shuwen Zhao frank.nies@sgcib.com

+1 212 278 5969

ramon.verastegui@sgcib.com james.hosker@sgcib.com shuwen.zhao@sgcib.com

+1 212 278 7548 +1 212 278 6291

APPENDIX I

Table 2 shows the TAS differential at settlement for November 8, 2012 for the March 2012 VIX Futures contract (UXH3). We can use the information to calculate the volume weighted price using the TAS execution prices.

Table 2. UXH3 (March 2013) VIX Futures Trade Recap at Settlement for 11/8/2012 , In Bloomberg <UXH3 Index>

Time	Size	Price	Trade Type
16:35:44	20	21.85	TAS
16:35:44	10	21.83	TAS
16:35:44	3	21.85	TAS
16:35:44	12	21.84	TAS
16:35:44	3	21.83	TAS
16:35:44	10	21.84	TAS
16:35:44	6	21.82	TAS
16:32:54		21.85	Settlement
Volume Weight using TAS on		21.84	

Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

Table 3 shows the TAS differential, order size and entry time for November 8, 2012 for the March 2012 VIX Futures contract (UXH3). We can use the information to calculate the volume weighted TAS differentials on the day. We calculate this each day and use it for our analysis in this report.

Table 3. UXH3 (March 2013) VIX Futures TAS Differential Recap for 11/8/2012, In Bloomberg <VXTH3 Index>

TAS Order Entry Time	Size	Price	Trade Type
16:32:54		0.00	Settlement
16:08:49	3	0.00	TAS
15:24:23	20	0.00	TAS
14:19:21	12	-0.01	TAS
13:15:21	3	-0.02	TAS
12:13:49	10	-0.01	TAS
12:13:38	10	-0.02	TAS
12:10:58	6	-0.03	TAS
Volume Weigh Differential on		-0.0103	

Source: Bloomberg, SG Global Engineering & Strategy, SG Trading

Global Equity Flow Strategy Team

Europe	Charles de Boissezon	charles.de-boissezon@sgcib.com	(+33) 1 4213 5841
	Delphine Leblond-Limpalaer	delphine.leblond@sgcib.com	(+44) 1 20 7762 5771
US	Ramon Verastegui	ramon.verastegui@sgcib.com	(+1) 212 278 6041
	James Hosker	james.hosker@sgcib.com	(+1) 212 278 6291
	Shuwen Zhao	shuwen.zhao@sgcib.com	(+1) 212 278 7268
Asia	Jean-Denis Ardon	jean-denis.ardon@sgcib.com	(+1) 852 2166 4573

IMPORTANT DISCLAIMER:

. . . .

This material is the product of Sales or Trading in the Global Markets Division of Societe Generale (SG) in the Americas. The material contains market commentary trading strategy and/or trade ideas. It is not a product of the Research Department and should not be regarded as a research report. It is directed only to institutional investors (as defined under NASD Rule 2211) and, when referencing options, is available only to such institutional investors who have received the proper options risk disclosure document. The securities and financial instruments discussed in this material may not be suitable for all institutional investors and investors must make their own investment decisions (using their own independent investment advisors as they may choose) and based upon specific financial situations and investment

Unless otherwise stated, any views or opinions expressed herein are solely those of the author and may differ from the views and opinions of the Research Department or other departments or divisions of SG and its affiliates. To the extent that this material contains short-term trade ideas based on macro views of economic or market conditions, they may differ from the longer-term views of the Research Department. This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. The information contained herein has been obtained from, and is based upon, sources believed to be reliable, but SG and its affiliates make no representation as to its accuracy and completeness. The views and opinions contained herein are those of the author of this material as of the date of this material and are subject to change without notice. Neither the author nor SG has any obligation to update, modify or otherwise notify the recipient in the event any information contained herein, including any opinion or view, changes or becomes inaccurate. Pricing levels, valuations and other data contained herein are indicative only and subject to change without notice. If this material references or mentions SG research, recipients are encouraged to read the full research report or note, which are available by accessing SG's Research Portal or by contacting SG

Recipients of this material should not consider the information contained herein to be objective or independent of SG's sales and trading businesses. As these are the views of an author in a specific sales or trading business, recipients should assume that the author of this material is an active participant in the markets, strategies and/or trading ideas contained herein.

SG and its affiliates and employees may have positions (long or short), effect transactions or make markets in any of the securities or financial instruments mentioned herein, or provide advice or loans to, or participate in the underwriting or restructuring of the obligations of, issuers mentioned herein. This material, including any data, may be considered by SG or any of its affiliates when deciding to buy or sell proprietary positions in any securities or financial instruments mentioned herein. SG and any of its affiliates may engage in transactions inconsistent with the views and opinions contained in this material and may sell to or buy from customers any of the securities or financial instruments mentioned herein on a principal or proprietary basis.

Unless expressly agreed in writing, Société Générale, SG Americas Securities, LLC and their affiliates (collectively, "SG") are not acting as an advisor or in an advisory capacity to any recipient of this document. In particular, SG is not acting as your fiduciary under Section 15B of the Securities Exchange Act of 1934, as amended (the "Act"), and our relationship will not otherwise be subject to the provisions of such Section 15B, the rules thereunder, or the rules issued by the Municipal Securities Rulemaking Board that relate to the provision of advice to municipal entities or their obligated persons.

Transactions in derivative instruments involve numerous risks including, among others, market, counterparty default and liquidity risk. Trading in options involves additional risks and is not suitable for all investors. An option may become worthless by its expiration date, as it is a depreciating asset. Option ownership could result in significant loss or gain, especially for options of unhedged positions. Prior to buying or selling an option, investors must review the "Characteristics and Risks of Standardized Options" at http://www.optionsclearing.com/publications/risks/riskchap.1.jsp.

Exchange Traded Funds (ETFs) are redeemable only in specified units and only through a broker that is an authorized participant in that ETF program. SG Americas Securities LLC ("SGAS") acts an authorized participant for a number of ETF programs and participates in the creation and redemption of ETFs, including ETFs that may be referenced in this material. SGAS, as an authorized participant or otherwise, may acquire securities of issuers of ETFs for the purpose of resale Redemptions are for the underlying securities. The public trading price of a redeemable unit of an ETF may be different from its net asset value. An ETF can trade at a discount or premium to the net asset value. There is always a risk of declining stock prices, which can cause investment losses. Clients should consider their investment objectives and the risks, charges and expenses of an ETF before investing. Each ETF prospectus contains such information and it is recommended that clients review such prospectus before investing. A copy of the prospectus for all ETFs mentioned in this material can be obtained from your SGAS salesperson at 1221 Avenue of the Americas, New York, NY, or from Customer Service at 480 Washington Blvd., Jersey City, NJ (1-800-861-9789). Prospectuses are also available from ETF distributors.

Clients should contact their salespersons to execute transactions through SG Americas Securities LLC ("SGAS") or an SG entity qualified in their home jurisdiction, unless governing law permits otherwise. SGAS is a member of FINRA, NYSE and SIPC.

Notice to French Investors: This document is issued in France by or through Société Générale which is regulated by the Autorite des Marches Financiers (AMF) Notice to U.K. Investors: This document is issued in the U.K. by or through Société Générale which is a member of the London Stock Exchange. Notice to Japanese Investors: This document is distributed in Japan Société Générale Securities (North Pacific) Ltd., Tokyo Branch which is regulated by the Financial Services Agency of Japan. The products mentioned in this report may not be eligible for sale in Japan and they may not be suitable for all types of Japanese investors. Notice to Australian Investors: Société Générale Australia Branch (ABN 71 092 516 286) takes responsibility for publishing this document. Société Générale holds an AFSL no. 236651 issued under the Corporations Act 2001 (Cth) ("Act"). The information contained in this document is only directed to recipients who are ware they are wholesale clients as defined under the Act.

Additional information is available upon request. This material should not be reproduced or redistributed without the specific consent of SGAS, SG or its affiliates. Copyright: 2012. Societe Generale (SG), SGAS, and their affiliates. All rights reserved.

www.sgcib.com

One-Delta Trading Engineering & Strategy

frank.nies@sgcib.com

+1 212 278 5969

Ramon Verastegui James Hosker Shuwen Zhao

ramon.verastegui@sgcib.com +1 212 278 7548 james.hosker@sgcib.com shuwen.zhao@sgcib.com

+1 212 278 6291 +1 212 278 7268